This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Well they are certainly making lots of new jobs gf as DB says their experience is useful at this stage in the companys development...says it all.

From the other side. Looks like we could soon be on the move.

With the caveat that U.S. broker Thomas Weisel has previously raised capital for Inovio, they issued this note yesterday, focussing attention on DNA vaccines.

For MMG-watchers, there is a highly significant excerpt from the recommendation of its GenVax division's DNA vaccine delivery partner: "Early human data on electroporation in at least one indication (e.g., prostate cancer and/or malignant melanoma) are expected in late May 2007, which could potentially lead to additional, large-scale partnerships for Inovio, in our view."

This is a clear reference to GenVax's Ph I/II trials - and yet another indication that the news, when it comes, is going to be big. And if its big for Inovio, it will likely be huge for MMG ... and will probably come with a rash of "second derivative" U.S. buying IMHO. Text follows :

Inovio Biomedical Corporation (INO; $3.72; Cap $130mn; Overweight) Initiating coverage with an Overweight rating.

Initiating coverage with an Overweight rating: We are initiating research coverage of Inovio Biomedical Corporation (INO) with an Overweight investment rating on the shares. We believe the companys electroporation technology represents a novel, tissue-sparing treatment option for cutaneous cancers with much broader applicability in various solid tumors. Although investors appear focused on this facet of Inovios business, we believe the companys gene delivery technology represents significantly untapped value, targeting multibillion-dollar market opportunities.

Proprietary electroporation technology: Inovios MedPulser instrument introduces localized electric pulses that open pores in cell membranes. This temporary poration allows for the entry of low dose chemotherapeutic agents for cancer therapy or larger proteins for the purpose of prophylactic or therapeutic vaccination or gene therapy.

Shows promise in oncology: In phase II studies, Inovio has demonstrated that combining electroporation with low doses of bleomycin resulted in complete responses (CR) of 26% in recurrent, late-stage head and neck (H&N) cancers and 80% CR in newly diagnosed H&N tumors. Two phase III H&N cancer trials are ongoing in the United States with results expected in 2009.

but value lies in gene delivery: We believe the real value in Inovio lies in its DNA vaccine and gene delivery business, which addresses extremely large markets including melanoma, HIV, hepatitis B and C, human papillomavirus and anthrax. Early human data on electroporation in at least one indication (e.g., prostate cancer and/or malignant melanoma) are expected in late May 2007, which could potentially lead to additional, large-scale partnerships for Inovio, in our view.

Valuation: Our 12-month price target of $8 is based on a sum-of-the-parts analysis of Inovios two business units: oncology and gene delivery. The companys oncology franchise comprises $1.60 of our price target (2012 SECTA revenue estimate discounted 25% annually and a 2.0x multiple) and gene delivery comprises $6.30 (40% of Pfizers $400mn PowderMed acquisition). Risks to our price target include: (1) disappointing early human results from Inovios DNA vaccine pipeline candidates, (2) failure to attract additional, exclusive partnerships in both oncology and gene delivery, (3) disappointing results from the companys ongoing phase III trials in SCCHN and/or phase I/II trial in breast cancer and (4) failure to raise additional capital either through a partnership or returning to the capital markets.

Estimates: Mar Q $1.1mn, $(0.10); Dec '07 $4.7mn, $(0.39); Dec 08 $4.5mn, $(0.39)

Yee-Haa...hang onto your hats !

el

I,m sticking with my prediction of 1500p within 2 years after all we went from 3p to 300p within 18 months 2 years ago.
I ma confident for 2007 being a great year for DB.

Gob smacked on that prediction.

You could be right .

Mitzy,

At 1500p, the market cap would be less than 1bn. If any one of MMG's 3 products passes all the tests, I reckon we could see a valuation in excess of this figure in the long term !!...

Long way to go though, and I agree with a 2-year target of 1500p.

NM

Hi neil:

Glad your a holder and plan to hold for 2 years like me.

Its a mini Glaxo to me with the chance of 3 therapies coming to the line at once...the DNA vaccines, Oncosense the novel anti cancer treatment, and the Hiv drugs.
Compared to Antisoma and OXB which are the nearest rivals MMG is valued at one third of their values so which ever way you try to put a value on the bio babies MMG are undervalued..

Hi Mitzy,

I've been a holder since August 2001, when I bought a few at 80p. I then watched them slip down to a few pence, and I remember thinking of selling them to cut my losses, only to realise that dealing charges etc would wipe out just about any return !! Over the years, I have instead added to my holdings, and I now have (what I would call) a reasonable size holding.

I am full of confidence for the future with this Company. I understand the risk involved, but the potential returns seem dramatic to say the least. Another 2 years isn't too long in the overall plan for me, but events may overtake us in the interim if one of the big pharmas decides they want MMG's developments for their own. If that does happen, from what I have seen, Dr Best will not allow a cheap takeover - he seems a very clever businessman as well as an expert on cancer treatment, and I believe we are in good hands!!

Good luck to all in MMG - enjoy the ride.


NM

Its certainly looking very positive.

Dr Best is a clever guy Neil and will not sell the company cheaply I believe he will hold out for at least 250p a share minimum.

Mitzy, I would imagine Dr Best has a much larger figure in mind.

Remember, he has stated that MMG are taking some trials to a later stage before involving partners, to get more value for shareholders by having a lower risk product to offer which will be much more attractive to the big boys (and much more expensive of course !)

I'm sure he will be thinking along the lines of at least 10+ per share , assuming the newsflow continues positively. Personally, I won't be selling at less than 10, unless the situation takes a marked turn for the worse, and the shares bomb.... This is looking more unlikely with every passing day however, as the story develops.

Remember also that there are 3 blockbuster drugs in the pipeline....Any one of them could command a 10 per share rating for MMG if they come good. If they ALL make the grade, than the sky is the limit !!

Get a feeling with todays announcement that Db is pushing the sales pitch as far as possible lets hope there is not too much hype this time.

Indeed mitzy.

We dont wont the cock up that went on last time.

We now have one of the strongest pipelines in the European biopharmaceutical development sector...

Lets hope they dont cock it up gf.

Looking forward to a good summer -- where will MMG be at the end of June??

Well the RU trials start in June so perhaps that will be the next stage in MMI,s development.

Looks good to me.

from another thread:


Just listening to the Webcast now & I quote David Best:

"More results of prostrate trials due at Malaga DNA conference, so this could be a pretty exciting time"

Slide 15 of 16 of the presentation also tells an interesting story:

SUMMARY

- Competitive product profiles in major markets
- Positive clinical data
- Significant news flow expected
- Proven low cost model, supportive major shareholders
- Global collaboration / licencing available

it all sounds quite positive.

more.....
A0469514 - 15 May'07 - 11:27 - 8448 of 8448


I have just watched Mr Best's presentation and was very impressed.

The chart showing the effectiveness of MMI's ruthenium compounds in killing cancer cells was particularly stunning. In every case the ruthenium compound was considerably more effective in the lab than any of the standard platinum products. In lung cancer it is over 100 times more effective than the current standard treatment, Carboplatin, with fewer side effects, no allergies and no resistance.

If that performance is replicated in the human trials coming shortly then the ruthenium family must be destined to be a huge winner. People might say that this is a big IF but ruthenium is very close to platinum chemically and from what I have seen now, it would be quite surprising to me if the ruthenium hit problems in the human trials.

Best again confirmed that they were negotiating with ALL the top 10 pharma companies and that they had various options open to them just waiting for the data.

I have some exciting companies in my portfolio but this one beats the lot.

Xylos

There should be more news at the Malaga conference from the 21st to the 26th of this month. Starting to look good, if only the sp would start to behave.

MS

Medical Marketing's Genvax immunostimulant gets immune response in cancer study
AFX


LONDON (Thomson Financial) - Medical Marketing International Group PLC said a phase I/II trial has shown that its Genvax immunostimulant technology can elicit cellular immune response in prostate cancer patients.

Preliminary data from a prostate cancer trial by the University of Southampton suggests that vaccines enhanced with the company's Genvax immunostimulant can be safely administered to cancer patients and are capable of getting a strong immune response, it said.

The company added that the results are very encouraging and suggest that the immune system can be engaged in the treatment of cancer.

Medical Marketing expects further data from the prostate cancer trial in the second half of 2007.

TFN.newsdesk@thomson.com

ash/faj/slm